Paclitaxel-Eluting vs. Bare-Metal Stents for Saphenous Vein Graft Lesions

In a small trial, PES recipients had lower restenosis and target-vessel revascularization rates 1 year after implantation.

Only one previous randomized study has been undertaken to assess the use of a drug-eluting stent (DES) for saphenous vein graft (SVG) lesions. In this new single-blind study, 80 patients with 112 SVG lesions were randomized to receive either paclitaxel-eluting stents (PES) or bare-metal stents (BMS). Baseline characteristics and procedural success were similar in the two groups. Distal protection devices were used in about half the procedures in both groups.

Angiographic follow-up was obtained for 80% of the lesions 1 year after stent implantation. The primary endpoint of in-segment binary restenosis occurred in 9% of PES lesions and in 51% of BMS lesions (P<0.0001). In-segment late loss was significantly lower with PES (0.36 mm) than with B…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI